Publications by authors named "Lloyd D W King"

Claim this Profile
S
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.
Hamtandi M Natama, Jo Salkeld, Athanase Somé, Seyi Soremekun, Salou Diallo, Lloyd D W King

Lancet Infect Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.
Sarah E Silk, Wilmina F Kalinga, Jo Salkeld, Ivanny M Mtaka, Saumu Ahmed, Lloyd D W King

Lancet Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5.
Thomas E Harrison, Nawsad Alam, Brendan Farrell, Doris Quinkert, Amelia M Lias, Lloyd D W King

EMBO Mol Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype.
Jordan R Barrett, Dimitra Pipini, Nathan D Wright, Andrew J R Cooper, Giacomo Gorini, Lloyd D W King, C Richter King

Cell· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plug and play virus-like particles for the generation of anti-toxin antibodies.
Rebecca J Edge, Amy E Marriott, Emma L Stars, Rohit N Patel, Mark C Wilkinson, Lloyd D W King

Toxicon X· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.
Lloyd D W King, David Pulido, Jordan R Barrett, Hannah Davies, Doris Quinkert, C Richter King

Cell Rep Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex.
Barnabas G Williams, Lloyd D W King, David Pulido, Doris Quinkert, Amelia M Lias, C Richter King

Nat Commun· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens.
Jordan R Barrett, Sarah E Silk, Catherine G Mkindi, Karolina M Kwiatkowska, Mimi M Hou, Lloyd D W King

Front Immunol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults.
Sarah E Silk, Wilmina F Kalinga, Ivanny M Mtaka, Nasoro S Lilolime, Maximillian Mpina, Lloyd D W King

Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination with Duffy-binding protein inhibits parasite growth during controlled human malaria infection.
Mimi M Hou, Jordan R Barrett, Yrene Themistocleous, Thomas A Rawlinson, Ababacar Diouf, Lloyd D W King, Lucy Kingham

Sci Transl Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting.
Julie Healer, Jennifer K Thompson, Karen L Mackwell, Cecille D Browne, Benjamin A Seager, Lloyd D W King

Front Cell Infect Microbiol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a blood-stage vaccine on malaria.
Mimi M Hou, Jordan R Barrett, Yrene Themistocleous, Thomas A Rawlinson, Ababacar Diouf, Lloyd D W King, Lucy Kingham

medRxiv· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein.
Robert J Ragotte, David Pulido, Francesca R Donnellan, Michelle L Hill, Giacomo Gorini, Lloyd D W King

mSphere· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies.
Alexandra C Willcox, Alex S Huber, Ababacar Diouf, Jordan R Barrett, Sarah E Silk, Lloyd D W King

Cell Rep Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-induced thrombi in mice develop asynchronously in the spleen and liver and are not effective bacterial traps.
Nonantzin Beristain-Covarrubias, Marisol Perez-Toledo, Adriana Flores-Langarica, Malou Zuidscherwoude, Jessica R Hitchcock, Lloyd D W King

Blood· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgG Responses to Porins and Lipopolysaccharide within an Outer Membrane-Based Vaccine against Nontyphoidal Develop at Discordant Rates.
Anna E Schager, C Coral Dominguez-Medina, Francesca Necchi, Francesca Micoli, Yun Shan Goh, Lloyd D W King

mBio· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of an extracellular bacterial flavoenzyme that can prevent re-polymerisation of lignin fragments.
Rahman Rahmanpour, Lloyd D W King, Timothy D H Bugg

Biochem Biophys Res Commun· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis